Table 2.

Description of cumulative variables after cohort entry

	Any AP (n=7118)	Cefepime (n=5274)	Meropenem (n=3625)	Piperacillin-tazobactam (n=2463)
Overall AP exposure (days), median (IQR)	7 (3–12)	5 (3–9)	7 (3–12)	4 (2–7)
Overall hospital days, median (IQR)	13 (7–24)	12 (6–23)	13 (6–25)	11 (6–21)
Days in ICU, median (IQR)	2 (0–8)	2 (0–8)	2 (0–9)	3 (0–7)
Mechanical ventilation days, median (IQR)	2 (0–7)	2 (0–8)	3 (0–9)	2 (0–7)
Central line days, median (IQR)	7 (1–17)	8 (2–19)	10 (3–21)	8 (2–16)
Urinary catheter days, median (IQR)	5 (0–12)	5 (0–13)	6 (1–14)	5 (1–12)

AP: antipseudomonal beta-lactam; IQR: interquartile range; ICU: intensive care unit